Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
EBIATLong-Term Debt RepaymentsWages, Salaries and Other
Ratios

Kraig Biocraft Laboratories (KBLB) Shares Issued (2016 - 2022)

Kraig Biocraft Laboratories (KBLB) has disclosed Shares Issued for 10 consecutive years, with $739864.0 as the latest value for Q1 2022.

  • Quarterly Shares Issued rose 733.33% to $739864.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $739864.0 through Dec 2022, up 177.8% year-over-year, with the annual reading at $739864.0 for FY2022, 177.8% up from the prior year.
  • Shares Issued hit $739864.0 in Q1 2022 for Kraig Biocraft Laboratories, up from $88774.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $1.0 million in Q1 2019 to a low of $88774.0 in Q2 2021.
  • Historically, Shares Issued has averaged $401239.2 across 3 years, with a median of $88784.0 in 2021.
  • Biggest YoY gain for Shares Issued was 733.33% in 2022; the steepest drop was 733.33% in 2022.
  • Year by year, Shares Issued stood at $1.0 million in 2019, then crashed by 91.12% to $88774.0 in 2021, then skyrocketed by 733.42% to $739864.0 in 2022.
  • Business Quant data shows Shares Issued for KBLB at $739864.0 in Q1 2022, $88774.0 in Q4 2021, and $88774.0 in Q2 2021.